Get complete Patent Opposition Report for Bioverativ Therapeutics

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Explore patent oppositions filed by Bioverativ Therapeutics against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent NumberTitleApplicantOpposition Date
EP3225233Sodium Chloride Solution For Drug Reconstitution Or DilutionWYETHMay 14, 2020
EP2256135Proteolytically Cleavable Fusion Protein Comprising A Blood Coagulation FactorCSL BEHRINGDec 13, 2019
EP2482841Compositions And Methods For Enhancing Coagulation Factor Viii FunctionTHE CHILDRENS HOSPITAL OF PHILADELPHIAAug 21, 2019

Explore Bioverativ Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP2956477Jan 24, 2024Optimized Factor Viii Gene1
EP2870250Jun 29, 2022Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses Thereof2